These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4418148)

  • 1. Inhibition by N-(phosphonacetyl)-L-aspartate of aspartate transcarbamylase activity and drug-induced cell proliferation in mice.
    Yoshida T; Stark GR; Hoogenraad J
    J Biol Chem; 1974 Nov; 249(21):6951-5. PubMed ID: 4418148
    [No Abstract]   [Full Text] [Related]  

  • 2. N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture.
    Swyryd EA; Seaver SS; Stark GR
    J Biol Chem; 1974 Nov; 249(21):6945-50. PubMed ID: 4371054
    [No Abstract]   [Full Text] [Related]  

  • 3. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
    Friedman J; Moore EC; Hall SW; Loo TL
    Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A facile enzymatic technique for the estimation of nanomolar concentrations of N-phosphonacetyl-L-aspartic acid in plasma.
    Kensler TW; Jayaram HN; Cooney DA
    J Biochem Biophys Methods; 1980; 2(1):29-35. PubMed ID: 6999068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
    Leyva A; Appel H; Smith P; Lankelma J; Pinedo HM
    Cancer Lett; 1981 Mar; 12(1-2):169-73. PubMed ID: 7273001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.
    Baillon J; Guichard M; Malaise EP; Hervé G
    Cancer Res; 1983 May; 43(5):2277-82. PubMed ID: 6831451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
    Johnson RK; Swyryd EA; Stark GR
    Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
    [No Abstract]   [Full Text] [Related]  

  • 8. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
    Cooney DA; Karlowicz MG; Cubillan J; Roettger M; Jayaram HN
    Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
    Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
    Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
    Kensler TW; Reck LJ; Cooney DA
    Cancer Res; 1981 Mar; 41(3):905-9. PubMed ID: 7459876
    [No Abstract]   [Full Text] [Related]  

  • 11. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
    Monks A; Anderson LW; Strong J; Cysyk RL
    J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The binding of N-(phosphonacetyl)-L-aspartate to aspartate carbamoyltransferase of Escherichia coli.
    Volź KW; Krause KL; Lipscomb WN
    Biochem Biophys Res Commun; 1986 Apr; 136(2):822-6. PubMed ID: 3518720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
    Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D
    Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosynthesis of pyrimidine nucleotides in mouse salivary glands stimulated with isoproterenol.
    Roux JM; Hoogenraad NJ; Kretchmer N
    J Biol Chem; 1973 Feb; 248(4):1196-202. PubMed ID: 4686922
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
    Grant S; Rauscher F; Jakubowski A; Cadman E
    Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
    Chadwick M; Silveira DM; MacGregor JA; Branfman AR; Liss RH; Yesair DW
    Cancer Res; 1982 Feb; 42(2):627-32. PubMed ID: 7055806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
    Moore EC
    Biochem Pharmacol; 1982 Oct; 31(20):3313-6. PubMed ID: 7150357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-phosphonacetyl-L-isoasparagine a potent and specific inhibitor of Escherichia coli aspartate transcarbamoylase.
    Eldo J; Cardia JP; O'Day EM; Xia J; Tsuruta H; Kantrowitz ER
    J Med Chem; 2006 Oct; 49(20):5932-8. PubMed ID: 17004708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of the 18 kDa and 22/24 kDa FGF-2 isoforms results in differential drug resistance and amplification potential.
    Dini G; Funghini S; Witort E; Magnelli L; Fanti E; Rifkin DB; Del Rosso M
    J Cell Physiol; 2002 Oct; 193(1):64-72. PubMed ID: 12209881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.
    White JC; Hines LH
    Biochem Pharmacol; 1984 Nov; 33(22):3645-8. PubMed ID: 6508821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.